Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 6/20 | 0.50 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21364620 | 0.84 | PIK3C3 (0.45) | MAPKAPK2KDM4ERAB9AL3MBTL1JAK2 | |
| SCHEMBL31696699 | 0.84 | MEN1 (0.51) | MAP4K1KDM4ERAB9AMEN1GLA | |
| SCHEMBL14826051 | 0.80 | PIK3C3 (0.51) | MEN1KMT2A | |
| SCHEMBL31696698 | 0.75 | KMT2A (0.47) | KDM4EMEN1GLAGAAKMT2A | |
| SCHEMBL17556225 | 0.74 | ACVR1 (0.68) | ACVR1 | |
| SCHEMBL19533011 | 0.74 | ALK (0.53) | ALKMAPKAPK2KDM4ERAB9AL3MBTL1 | |
| SCHEMBL3324055 | 0.73 | DRD2 (0.46) | — | |
| SCHEMBL16965450 | 0.72 | JAK2 (0.56) | ALKMAPKAPK2KDM4ERAB9AL3MBTL1 | |
| SCHEMBL21364619 | 0.72 | PIK3C3 (0.46) | KDM4ERAB9AGLAGAA | |
| SCHEMBL31380997 | 0.72 | PIK3C3 (0.49) | RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200054643-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | VANDERBILT UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
| US-20200054643-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | VANDERBILT UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
| US-10196392-B2 | Fused heterocyclic compounds as selective BMP inhibitors | VANDERBILT UNIVERSITY (US) | 2019-02-05 | — | — | US | disclosed |
| US-10196392-B2 | Fused heterocyclic compounds as selective BMP inhibitors | VANDERBILT UNIVERSITY (US) | 2019-02-05 | — | — | US | disclosed |
| WO-2018136634-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | VANDERBILT UNIVERSITY (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018136634-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | VANDERBILT UNIVERSITY (US) | 2018-07-26 | — | — | WO | disclosed |
| EP-2900238-B1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | UNIV VANDERBILT (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2900238-B1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | UNIV VANDERBILT (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20170313701-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | VANDERBILT UNIVERSITY | 2017-11-02 | — | — | US | disclosed |
| US-20170313701-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | VANDERBILT UNIVERSITY | 2017-11-02 | — | — | US | disclosed |
| US-20170313701-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | VANDERBILT UNIVERSITY | 2017-11-02 | — | — | US | disclosed |
| US-9738636-B2 | Fused heterocyclic compounds as selective BMP inhibitors | VANDERBILT UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738636-B2 | Fused heterocyclic compounds as selective BMP inhibitors | VANDERBILT UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738636-B2 | Fused heterocyclic compounds as selective BMP inhibitors | VANDERBILT UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160068525-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | VANDERBILT UNIVERSITY (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068525-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | VANDERBILT UNIVERSITY (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068525-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | VANDERBILT UNIVERSITY (US) | 2016-03-10 | — | — | US | disclosed |
| EP-2900238-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | Vanderbilt University (US) | 2015-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196392-B2 | Fused heterocyclic compounds as selective BMP inhibitors | BMP1, BMP4, BMP2 | ACVR1 9/4885MAP4K1 381/4885ALK 290/4885 |
| US-20200054643-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | BMP1, BMP4, BMPR2 | ACVR1 9/4885MAP4K1 371/4885ALK 69/4885 |
| US-20170313701-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | BMP1, BMP4, BMP2 | ACVR1 9/4885MAP4K1 381/4885ALK 290/4885 |
| US-20160068525-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | BMP1, BMP4, BMP2 | ACVR1 9/4885MAP4K1 381/4885ALK 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.